Literature DB >> 6847629

Binding of platelet factor 4 to heparin oligosaccharides.

J Denton, D A Lane, L Thunberg, A M Slater, U Lindahl.   

Abstract

Heparin fractions of differing Mr (7800-18 800) prepared from commercial heparin by gel filtration and affinity chromatography on immobilized anti-thrombin III had specific activities when determined by anti-Factor Xa and anti-thrombin assays that ranged from 228 to 448 units/mg. The anti-Factor Xa activity of these fractions could be readily and totally neutralized by increasing concentrations of platelet factor 4 (PF4). That these fractions bound to immobilized PF4 was indicated by the complete binding under near physiological conditions of 3H-labelled unfractionated commercial heparin. An anti-thrombin III-binding oligosaccharide preparation (containing predominantly eight to ten saccharide units), prepared by degradation of heparin with HNO2 had high (800 units/mg) anti-Factor Xa, but negligible anti-thrombin, specific activity. The anti-Factor Xa activity of this material could not be readily neutralized by PF4, and the 3H-labelled oligosaccharides did not completely bind to immobilized PF4. A heterogeneous anti-thrombin III-binding preparation containing upwards of 16 saccharides had anti-thrombin specific activity of just less than one-half the anti-Factor Xa specific activity. This material was completely bound to immobilized PF4 and was eluted with similar concentrations of NaCl to those that were required to elute unfractionated heparins from these columns. Furthermore, increasing concentrations of PF4 neutralized the anti-Factor Xa activity of this material in a manner similar to that of unfractionated heparin. It is concluded that heparin oligosaccharides require saccharide units in addition to the anti-thrombin III-binding sequence in order to fully interact with PF4.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847629      PMCID: PMC1154112          DOI: 10.1042/bj2090455

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G E Sims
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

2.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

3.  Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin.

Authors:  M Höök; I Björk; J Hopwood; U Lindahl
Journal:  FEBS Lett       Date:  1976-07-01       Impact factor: 4.124

4.  The heparin-thrombin complex in the mechanism of thrombin inactivation by heparin.

Authors:  G F Smith
Journal:  Biochem Biophys Res Commun       Date:  1977-07-11       Impact factor: 3.575

5.  Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule.

Authors:  S Niewiarowski; B Rucinski; P James; U Lindahl
Journal:  FEBS Lett       Date:  1979-06-01       Impact factor: 4.124

6.  Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4 ) released from human blood platelets.

Authors:  A J Barber; R Käser-Glanzmann; M Jakábová; E F Lüscher
Journal:  Biochim Biophys Acta       Date:  1972-12-29

7.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.

Authors:  A N Teien; M Lie
Journal:  Thromb Res       Date:  1977-03       Impact factor: 3.944

8.  Platelet antiheparin activity. The isolation and characterisation of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound antiheparin activity.

Authors:  S Moore; D S Pepper; J D Cash
Journal:  Biochim Biophys Acta       Date:  1975-02-27

9.  Action of heparin on thrombin-antithrombin reaction.

Authors:  R Machovich; G Blaskó; L A Pálos
Journal:  Biochim Biophys Acta       Date:  1975-01-30

10.  Purification and binding properties of human platelet factor four.

Authors:  R I Handin; H J Cohen
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

View more
  15 in total

1.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

2.  Exposure to acrolein by inhalation causes platelet activation.

Authors:  Srinivas D Sithu; Sanjay Srivastava; Maqsood A Siddiqui; Elena Vladykovskaya; Daniel W Riggs; Daniel J Conklin; Petra Haberzettl; Timothy E O'Toole; Aruni Bhatnagar; Stanley E D'Souza
Journal:  Toxicol Appl Pharmacol       Date:  2010-08-03       Impact factor: 4.219

Review 3.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

4.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

5.  Binding of heparin to human platelet factor 4.

Authors:  S W Cowan; E N Bakshi; K J Machin; N W Isaacs
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

6.  2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia.

Authors:  Elizabeth Tkaczynski; Abinaya Arulselvan; John Tkaczynski; Stephen Avery; Liqing Xiao; Beverly Torok-Storb; Kraig Abrams; Narayanam V Rao; Gregory Johnson; Thomas P Kennedy; Mortimer Poncz; Michele P Lambert
Journal:  Blood Adv       Date:  2018-04-10

7.  The role of platelet factor 4 in radiation-induced thrombocytopenia.

Authors:  Michele P Lambert; Liqing Xiao; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-01       Impact factor: 7.038

8.  Identification and characterization of PF4varl, a human gene variant of platelet factor 4.

Authors:  C J Green; R S Charles; B F Edwards; P H Johnson
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

9.  Comparative studies of the interaction of human and bovine platelet factor 4 with heparin using histidine NMR resonances as spectroscopic probes.

Authors:  C J Talpas; L Lee
Journal:  J Protein Chem       Date:  1993-06

10.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.